Theralase Technologies bladder cancer treatment shows promising results in Phase 2 study – ICYMI [Video]

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) CEO Roger Dumoulin-White joined Proactive to discuss the latest developments for the company’s lead drug, Ruvidar, which is targeting non-muscle invasive bladder cancer.

Dumoulin-White shared updates from their ongoing Phase 2 registration study, in which Theralase’s treatment is achieving impressive results, with three out of five patients becoming cancer-free after just one treatment session.

Proactive: Could you give us an update on how Theralase is progressing with your lead cancer treatment?

Roger Dumoulin-White: Yes, sure. Our lead drug is Ruvidar, which targets non-muscle invasive bladder cancer. We’re currently in a Phase 2 registration study. We’ve enrolled 75 patients so far, and we’ve evaluated 68 of them at the 90-day mark.

What are the key results you’re seeing in these patients?

We’re showing a complete response rate for patients of 60% at any point in time, which is quite remarkable. That means three out of five patients are becoming cancer-free after just one treatment.

That’s impressive. How long …